MARKET

GNPX

GNPX

Genprex Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.370
+0.140
+4.33%
Closed 19:43 12/01 EST
OPEN
3.250
PREV CLOSE
3.230
HIGH
3.490
LOW
3.230
VOLUME
1.12M
TURNOVER
--
52 WEEK HIGH
7.03
52 WEEK LOW
0.2310
MARKET CAP
133.52M
P/E (TTM)
-6.3120
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Genprex Initiates Site Recruitment For Acclaim-1 Clinical Trial For Treatment Of Non-Small Cell Lung Cancer
Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer Acclaim-1 trial combines REQORSA™ immunogene therapy drug with AstraZeneca's
Benzinga · 1d ago
Diamond Equity Research 2020 Virtual Emerging Growth Invitational
" stated Hunter Diamond, CFA the CEO of Diamond Equity Research.
ACCESSWIRE · 11/24 14:30
Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1
Genprex's COO will present on December 1 at the Diamond Equity Research Emerging Growth Invitational
Business Wire · 11/24 13:16
Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing
Genprex appoints Eric Chapdelaine to VP of Manufacturing
Business Wire · 10/26 12:16
Genprex (GNPX) Investor Presentation - Slideshow
The following slide deck was published by Genprex, Inc. in conjunction with this event.
Seekingalpha · 10/16 17:05
Genprex to Present at Zooming with LD Micro on October 14, 2020
Genprex will present at the Zooming with LD Micro virtual event
Business Wire · 10/07 12:17
Genprex to Present at the Alliance for Regenerative Medicines Virtual Cell and Gene Meeting on the Mesa
Genprex will present at the Cell and Gene Meeting on the Mesa
Business Wire · 10/06 13:16
Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing
Genprex hires Senior Vice President of IP and Licensing
Business Wire · 09/21 12:17
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GNPX. Analyze the recent business situations of Genprex Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GNPX stock price target is 6.67 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 74
Institutional Holdings: 5.12M
% Owned: 12.91%
Shares Outstanding: 39.62M
TypeInstitutionsShares
Increased
15
243.58K
New
24
-78.12K
Decreased
17
222.55K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.30%
Pharmaceuticals & Medical Research
+0.62%
Key Executives
Chairman/President/Chief Executive Officer/Secretary/Director
J. Rodney Varner
Chief Financial Officer
Ryan Confer
Chief Operating Officer/Executive Vice President
Michael Redman
Executive Vice President
Catherine Vaczy
Independent Director
Brent Longnecker
Independent Director
Jose Moreno Toscano
Independent Director
William Wilson
Director
Will Wilson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on developing cancer-based upon its novel technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. Oncoprex consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects and is thereby considered an immunogene therapy. The gene is one of a series of genes whose therapeutic use is covered by a license from The University of Texas MD Anderson Cancer Center (MD Anderson). It is also developing a pre-clinical gene therapy that is covered by a license from the University of Pittsburgh of the Commonwealth System of Higher Education that has the potential to cure type 1 and type 2 diabetes. It is developing its product candidate to be administered with targeted therapies and with immunotherapies for non-small cell lung cancer (NSCLC).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Genprex Inc stock information, including NASDAQ:GNPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNPX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNPX stock methods without spending real money on the virtual paper trading platform.